Halozyme Therapeutics: director Daly J M received 1,169 RSUs, 1,775 options

What happened

• Daly James M, a director of Halozyme Therapeutics, was granted 1,169 restricted stock units and granted 1,775 stock options on Oct 1, 2026. Both transactions are recorded at $0.

Key details

• Transaction date and price: Oct 1, 2026 — 1,169 RSUs at $0; Oct 1, 2026 — 1,775 options at $0 (derivative).
• Shares owned after the transaction: not reported in this filing.
• Footnotes: F1 — the 1,169 RSUs represent the right to receive one share per unit and are scheduled to vest on the date of the issuer's 2027 annual meeting of stockholders. F2 — the 1,775 options were granted under the director compensation program and will vest in full on the date of the issuer's 2027 annual meeting of stockholders.
• Filing date: Oct 2, 2026; the filing does not indicate a late filing.

Why it may matter

• These entries are grants (an RSU award and an option award), not open-market purchases or sales.
• The option grant is not an exercise; no shares were exercised or sold in this filing.
• This filing does not show why the insider traded or why the company acted.